# EDGAR Filing Document

**Accession Number:** 0001346824
**File Stem:** 0001104659-25-085720
**Filing Date:** 2025-8
**Character Count:** 32716
**Document Hash:** 113eddd61172e7f003ef7bd6f5af7ad7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-085720.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001104659-25-085720

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RA CAPITAL MANAGEMENT, L.P.
- **CENTRAL INDEX KEY:** 0001346824

**ORGANIZATION NAME:**
- **EIN:** 830406777
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-12884
- **FILM NUMBER:** 251281346

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET, 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-778-2500

**MAIL ADDRESS:**
- **STREET 1:** 200 BERKELEY STREET, 18TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RA CAPITAL MANAGEMENT, LLC
- **DATE OF NAME CHANGE:** 20051213

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001346824

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** RA CAPITAL MANAGEMENT, L.P.

**Address:** 200 Berkeley St., Boston, MA 02116

**Telephone number:** 617-778-2500

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-12884

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                   | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                    | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   | SHARES VOTED FOR OR AGAINST MANAGEMENT   | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|:---|:---|:---|
| UroGen Pharma Ltd.               | M96088105 | 08/06/2024     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.                                                                 | SECTION 14A SAY-ON-PAY VOTES |      3.08291e+06 |                0 | FOR         | 3082911.000000                           | FOR                         |  |
| Wave Life Sciences Ltd.          | Y95308105 | 08/06/2024     | To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statement                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |      5.21365e+06 |                0 | FOR         | 5213651.000000                           | FOR                         |  |
| Wave Life Sciences Ltd.          | Y95308105 | 08/06/2024     | To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statement                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |      1.29884e+07 |                0 | FOR         | 12988358.000000                          | FOR                         |  |
| Rhythm Pharmaceuticals, Inc.     | 76243J105 | 09/18/2024     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      3.94449e+06 |                0 | FOR         | 3944490.000000                           | FOR                         |  |
| Enanta Pharmaceuticals, Inc.     | 29251M106 | 03/13/2025     | To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation paid to our named executive officers.                                                                                               | SECTION 14A SAY-ON-PAY VOTES |  83190           |                0 | ONE YEAR    | 83190.000000                             | FOR                         |  |
| Enanta Pharmaceuticals, Inc.     | 29251M106 | 03/13/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |  83190           |                0 | FOR         | 83190.000000                             | FOR                         |  |
| Larimar Therapeutics, Inc.       | 517125100 | 05/13/2025     | Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers in 2024                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      5.70906e+06 |           336293 | FOR         | 5709058.000000                           | FOR                         |  |
| Insmed Incorporated              | 457669307 | 05/15/2025     | An advisory vote on the 2024 compensation of our named executive officers.                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES | 200000           |                0 | FOR         | 200000.000000                            | FOR                         |  |
| Geron Corporation                | 374163103 | 05/21/2025     | To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |      6.03794e+07 |                0 | FOR         | 60379366.000000                          | FOR                         |  |
| Dianthus Therapeutics, Inc.      | 252828108 | 05/22/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers; and                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      2.86673e+06 |                0 | FOR         | 2866733.000000                           | FOR                         |  |
| SCHOLAR ROCK HOLDING CORPORATION | 80706P103 | 05/22/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES | 179519           |                0 | FOR         | 179519.000000                            | FOR                         |  |
| 89bio, Inc.                      | 282559103 | 05/28/2025     | Approval of, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.66121e+06 |                0 | FOR         | 1661214.000000                           | FOR                         |  |
| 89bio, Inc.                      | 282559103 | 05/28/2025     | Approval of, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.06815e+07 |                0 | FOR         | 10681478.000000                          | FOR                         |  |
| Arcellx, Inc.                    | 03940C100 | 05/28/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.                                | SECTION 14A SAY-ON-PAY VOTES |      2.88474e+06 |           151785 | FOR         | 2884742.000000                           | FOR                         |  |
| Acadia Healthcare Company, Inc.  | 00404A109 | 05/29/2025     | Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement.                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |      0           |           217000 |  |  |  |  |
| Acadia Healthcare Company, Inc.  | 00404A109 | 05/29/2025     | Advisory vote on the frequency of a non-binding advisory vote on the Compensation of the Company's named executive officers.                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      0           |           217000 |  |  |  |  |
| Glaukos Corporation              | 377322102 | 05/29/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |  71801           |                0 | FOR         | 71801.000000                             | FOR                         |  |
| Dyne Therapeutics, Inc.          | 26818M108 | 05/30/2025     | To vote, on an advisory basis, to approve the compensation of our named executive officers.                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      2.91264e+06 |           101760 | FOR         | 2912641.000000                           | FOR                         |  |
| Dyne Therapeutics, Inc.          | 26818M108 | 05/30/2025     | To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      2.91264e+06 |           101760 | ONE YEAR    | 2912641.000000                           | FOR                         |  |
| Day One Biopharmaceuticals, Inc. | 23954D109 | 06/02/2025     | Approval, on a non-binding advisory basis, of the compensation of our named executive officers.                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      4.91333e+06 |                0 | FOR         | 4913327.000000                           | FOR                         |  |
| 10X Genomics, Inc.               | 88025U109 | 06/03/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      1.6551e+06  |                0 | AGAINST     | 1655103.000000                           | AGAINST                     |  |
| RxSight, Inc.                    | 78349D107 | 06/03/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.                                | SECTION 14A SAY-ON-PAY VOTES |      3.56356e+06 |            71381 | FOR         | 3563560.000000                           | FOR                         |  |
| NewAmsterdam Pharma Company N.V. | N62509109 | 06/04/2025     | Non-binding, advisory vote to approve the 2024 compensation of named executive officers.                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |      3e+06       |                0 | FOR         | 3000000.000000                           | FOR                         |  |
| NewAmsterdam Pharma Company N.V. | N62509109 | 06/04/2025     | Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      3e+06       |                0 | ONE YEAR    | 3000000.000000                           | FOR                         |  |
| NewAmsterdam Pharma Company N.V. | N62509109 | 06/04/2025     | Non-binding, advisory vote to approve the 2024 compensation of named executive officers.                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |      5.6255e+06  |            28612 | FOR         | 5625498.000000                           | FOR                         |  |
| NewAmsterdam Pharma Company N.V. | N62509109 | 06/04/2025     | Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      5.6255e+06  |            28612 | ONE YEAR    | 5625498.000000                           | FOR                         |  |
| Aclaris Therapeutics, Inc.       | 00461U105 | 06/05/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card.                                                                               | SECTION 14A SAY-ON-PAY VOTES | 501075           |           649121 | FOR         | 501075.000000                            | FOR                         |  |
| Kura Oncology, Inc.              | 50127T109 | 06/05/2025     | Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the proxy statement.                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |      3.95764e+06 |            46973 | FOR         | 3957637.000000                           | FOR                         |  |
| Sutro Biopharma, Inc.            | 869367102 | 06/06/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      3.34117e+06 |           174861 | FOR         | 3341169.000000                           | FOR                         |  |
| Arcus Biosciences, Inc.          | 03969F109 | 06/10/2025     | To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      1.0294e+06  |                0 | FOR         | 1029400.000000                           | FOR                         |  |
| Avidity Biosciences, Inc.        | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and | SECTION 14A SAY-ON-PAY VOTES |      5.15602e+06 |           189128 | FOR         | 5156024.000000                           | FOR                         |  |
| Adicet Bio, Inc.                 | 007002108 | 06/11/2025     | To ratify, on a non-binding advisory basis, the compensation of our named executive officers.                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      6.69791e+06 |                0 | FOR         | 6697908.000000                           | FOR                         |  |
| Alector, Inc.                    | 014442107 | 06/11/2025     | Advisory vote on executive compensation.                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |      7.09866e+06 |                0 | FOR         | 7098663.000000                           | FOR                         |  |
| Astria Therapeutics, Inc.        | 04635X102 | 06/11/2025     | The approval, by non-binding advisory vote, of our executive compensation.                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      4.04109e+06 |           426655 | FOR         | 4041091.000000                           | FOR                         |  |
| Disc Medicine, Inc.              | 254604101 | 06/11/2025     | To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.57711e+06 |                0 | FOR         | 1577106.000000                           | FOR                         |  |
| Disc Medicine, Inc.              | 254604101 | 06/11/2025     | To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers.                                                                            | SECTION 14A SAY-ON-PAY VOTES |      1.57711e+06 |                0 | ONE YEAR    | 1577106.000000                           | FOR                         |  |
| Janux Therapeutics, Inc.         | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                               | SECTION 14A SAY-ON-PAY VOTES |      6.82451e+06 |                0 | FOR         | 6824511.000000                           | FOR                         |  |
| Janux Therapeutics, Inc.         | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                | SECTION 14A SAY-ON-PAY VOTES |      6.82451e+06 |                0 | ONE YEAR    | 6824511.000000                           | FOR                         |  |
| Janux Therapeutics, Inc.         | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.                                                                               | SECTION 14A SAY-ON-PAY VOTES |      3.46324e+06 |                0 | FOR         | 3463235.000000                           | FOR                         |  |
| Janux Therapeutics, Inc.         | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.                                                                                | SECTION 14A SAY-ON-PAY VOTES |      3.46324e+06 |                0 | ONE YEAR    | 3463235.000000                           | FOR                         |  |
| Protara Therapeutics, Inc.       | 74365U107 | 06/11/2025     | Approval, on an advisory basis, of the compensation of Protara Therapeutics, Inc.'s named executive officers, as disclosed in the proxy statement                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      1.9e+06     |                0 | FOR         | 1900000.000000                           | FOR                         |  |
| Protara Therapeutics, Inc.       | 74365U107 | 06/11/2025     | Approval, on an advisory basis, of the compensation of Protara Therapeutics, Inc.'s named executive officers, as disclosed in the proxy statement                                                                                   | SECTION 14A SAY-ON-PAY VOTES | 841636           |            71838 | FOR         | 841636.000000                            | FOR                         |  |
| Solid Biosciences Inc.           | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      3.01363e+06 |                0 | FOR         | 3013630.000000                           | AGAINST                     |  |
| Solid Biosciences Inc.           | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      1.57398e+06 |            42072 | FOR         | 1573983.000000                           | FOR                         |  |
| Vaxcyte, Inc.                    | 92243G108 | 06/12/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |      1.13477e+07 |            32496 | FOR         | 11347663.000000                          | FOR                         |  |
| Xencor, Inc.                     | 98401F105 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement;                                                                       | SECTION 14A SAY-ON-PAY VOTES | 270000           |                0 | FOR         | 270000.000000                            | FOR                         |  |
| Edgewise Therapeutics, Inc.      | 28036F105 | 06/13/2025     | Conduct an advisory vote on the compensation of our named executive officers.                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      8.27534e+06 |           394542 | FOR         | 8275345.000000                           | FOR                         |  |
| Edgewise Therapeutics, Inc.      | 28036F105 | 06/13/2025     | Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      8.27534e+06 |           394542 | ONE YEAR    | 8275345.000000                           | FOR                         |  |
| 4D Molecular Therapeutics, Inc.  | 35104E100 | 06/17/2025     | Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      4.39994e+06 |           128454 | FOR         | 4399945.000000                           | FOR                         |  |
| 4D Molecular Therapeutics, Inc.  | 35104E100 | 06/17/2025     | Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      4.39994e+06 |           128454 | ONE YEAR    | 4399945.000000                           | FOR                         |  |
| Apogee Therapeutics, Inc.        | 03770N101 | 06/17/2025     | Vote on the frequency of future advisory votes to approve our named executive officers compensation.                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 100000           |           753737 | ONE YEAR    | 100000.000000                            | FOR                         |  |
| Avalo Therapeutics, Inc.         | 05338F306 | 06/17/2025     | To approve, on a nonbinding advisory basis, a "Say-on-Pay" resolution regarding the compensation of our named executive officers;                                                                                                   | SECTION 14A SAY-ON-PAY VOTES | 942652           |              766 | FOR         | 942652.000000                            | FOR                         |  |
| Monopar Therapeutics Inc.        | 61023L207 | 06/17/2025     | To approve the compensation of our named executive officers on an advisory, non-binding basis.                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES | 508435           |             2772 | FOR         | 508435.000000                            | FOR                         |  |
| Monopar Therapeutics Inc.        | 61023L207 | 06/17/2025     | To approve the frequency of future advisory votes on the compensation of our named executive officers on an advisory, non-binding basis                                                                                             | SECTION 14A SAY-ON-PAY VOTES | 508435           |             2772 | ONE YEAR    | 508435.000000                            | FOR                         |  |
| Cidara Therapeutics, Inc.        | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 793036           |                0 | FOR         | 793036.000000                            | AGAINST                     |  |
| Cidara Therapeutics, Inc.        | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.                                                                                                | SECTION 14A SAY-ON-PAY VOTES | 389716           |                0 | FOR         | 389716.000000                            | FOR                         |  |
| EyePoint Pharmaceuticals, Inc.   | 30233G209 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      3.18182e+06 |                0 | FOR         | 3181818.000000                           | FOR                         |  |
| EyePoint Pharmaceuticals, Inc.   | 30233G209 | 06/18/2025     | To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.                                                                                             | SECTION 14A SAY-ON-PAY VOTES |      3.18182e+06 |                0 | ONE YEAR    | 3181818.000000                           | FOR                         |  |
| Zai Lab Limited                  | 98887Q104 | 06/18/2025     | THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 618717           |            58188 | FOR         | 618717.000000                            | FOR                         |  |
| Structure Therapeutics Inc.      | 86366E106 | 06/23/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      1.33949e+06 |                0 | FOR         | 1339491.000000                           | FOR                         |  |
| Structure Therapeutics Inc.      | 86366E106 | 06/23/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.                                                                             | SECTION 14A SAY-ON-PAY VOTES |      1.33949e+06 |                0 | ONE YEAR    | 1339491.000000                           | FOR                         |  |
| IDEAYA Biosciences, Inc.         | 45166A102 | 06/24/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders.                            | SECTION 14A SAY-ON-PAY VOTES | 240000           |                0 | FOR         | 240000.000000                            | FOR                         |  |
| Rhythm Pharmaceuticals, Inc.     | 76243J105 | 06/24/2025     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      5.49112e+06 |                0 | FOR         | 5491123.000000                           | FOR                         |  |
| Fulcrum Therapeutics, Inc.       | 359616109 | 06/26/2025     | A non-binding advisory vote on executive compensation;                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |      9.33272e+06 |            64351 | FOR         | 9332719.000000                           | FOR                         |  |
| Fulcrum Therapeutics, Inc.       | 359616109 | 06/26/2025     | A non-binding advisory vote on the frequency of future executive compensation advisory votes; and                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |      9.33272e+06 |            64351 | ONE YEAR    | 9332719.000000                           | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** RA CAPITAL MANAGEMENT, L.P.

**By (Signature):** Rajeev Shah

**By (Printed Signature):** Rajeev Shah

**By (Title):** Authorized Signatory

**Date:** 08/29/2025